Rhopressa: Ph III Rocket 4 data

Top-line data from the double-blind, U.S. Phase III Rocket 4 trial in about 700 patients with glaucoma or ocular hypertension showed that once-daily 0.02% Rhopressa eye drops met the primary endpoint ...